Basilea says Canadian regulatory authority accepts Ceftobiprole for review |
|
|
|
Published
:
Fri, 14 Sep 2007 06:46 |
ZURICH (Thomson Financial) - Basilea Pharmaceutica AG said the Therapeutic Products Directorate of Health Canada has accepted the New Drug Submission of Ceftobiprole, a treatment for complicated skin and skin structure infections including diabetic foot infections, for review.The regulatory dossier was submitted by Basilea's license partner Janssen-Ortho, a Johnson & Johnson company.johanna.treeck@thomson.comjmt/sljCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
2792.28 |
22.57 (
0.81 %)
|
| SYMBOL (
2012-01-19 ) |
| LAST |
CHANGE
|
|
CARNIVAL
(
11:35am )
|
|
2017.00 |
46.00 (
2.42 %)
|
|
WHITBREAD
(
11:35am )
|
|
1662.99 |
33.99 (
2.09 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
IBM
(
12:34pm ) |
|
181.50 |
0.43 (
0.24 %)
|
| SYMBOL (
2012-01-19 )
|
| LAST |
CHANGE
|
|
| Portfolio
Manager |
|
|
|